Starting from September 2022, EqualOcean had been conducting deep market research and expert interviews aiming to select out 30 most representative China-based companies in the AI Health sector. It is finally officially finalized, and we give our deep and sincere congratulations to those 30 companies and wish them all the best in the future. The 30 companies with the most growth and development potential in the field of AI healthcare in China in 2022 will be selected.
‘AI Health’ or ‘AI in Health’ can be simply defined as the implementation of Artificial Intelligence (AI) in the medical and healthcare fields. To be specific, from the basic medical record management to the tedious and repetitive processes like medical imaging, to the hard novel drug target discovery, all can be assisted by AI technology. The employment of AI in healthcare fields does not only reduce costs, improve efficiency but also can promote the equalization of quality medical resources in China.
The 20th National Congress of the Chinese Communist Party (CCP) held in October 2022 also mentioned about "Building a healthy China" which included "promoting the expansion of quality medical resources and the balanced distribution of regional distribution, strengthening the health management of major chronic diseases, and improving the community-level capacity of disease prevention and treatment and health management".
In addition, China has a large population base which allows for the generation of large amount of medical data and worldwide top-tanking AI scientific research output and achievement. These natural advantages establish the solid foundation for the development of AI Health industry in China and nourish a batch of local AI medical and health innovation enterprises.
At the same time, as an emerging force in the global biomedical and medical technology industry, China's development in the field of AI Health can also provide insights into the development trend and direction of the global AI Health industry.
Based on the above, EqualOcean released the "China AI Health 30 List 2022", which focuses on six sub-sectors: AI+ drug discovery, AI+ medical imaging, AI+ surgery robotics, AI+ disease diagnosis and treatment, AI+ health management, and AI+ Clinical Decision Support System (CDSS).
The selection criteria were set on the following four dimensions: talent background, R&D capability, technical level, product and service capability:
1) The distribution of different levels of working experience of R&D personnel and management personnel.
2) The proportion of employees with AI+medical interdisciplinary backgrounds, the proportion of employees with doctor's degree or above, and the proportion with overseas background.
3) The distinct features of database, the number of patents obtained, the quality of publications, and international R&D collaborations.
4) Types and numbers of collaborations or partnerships.
In the end, EqualOcean successfully shortlisted 30 companies with outstanding performance in the six segments above. The list is as follows:
The top three sub-sectors with the most companies on the list are: AI+ medical imaging (seven), AI+ drug discovery (six) and AI+ medical robotics (five).